Sign in
Taking people in United StatesNo phase

Treating insomnia before a weight loss program in breast cancer survivors

Tests whether treating insomnia first helps weight loss in breast cancer survivors with overweight.

Key facts

Who runs it
Johns Hopkins University
Where
Baltimore, Lutherville, and Washington D.C., United StatesSee the 4 sites
Trial code
Registry title
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
Status
Recruiting
People taking part
250 people, planned
Started
1 Feb 2024
Expected to end
31 Dec 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Cognitive-Behavioral Therapy for Insomnia (CBT-I)
  • Sleep Education Control (EDU)
Record updated
23 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women who had early stage breast cancer, are overweight or obese, and have insomnia. It tests whether treating insomnia before a weight loss program helps weight loss.

Age
18 years or older
Sex
Women only
Disease stage
DCIS (Ductal Carcinoma In Situ) or stage I-III invasive breast cancer, confirmed by tissue test and diagnosed within 10 years. ECOG performance status 0-2, meaning you can still do most daily activities. Insomnia disorder by DSM-5 criteria, lasting 3 months or more.
Earlier treatment
Surgery and radiation, and any planned chemotherapy, immunotherapy, HER2 therapy or targeted therapy, must be finished at least 3 months before joining. Hormone (endocrine) therapy at the same time is allowed. All planned surgeries must be finished more than 4 weeks before joining.
Biomarker or test result
BMI ≥ 25 kg/m2 and weight ≤ 400 lbs (181 kg). Insomnia Severity Index Score ≥ 9. Taking more than 30 minutes to fall asleep or awake more than 30 minutes at night, more than 3 nights a week.

Main reasons for not taking part

  • Serious or uncontrolled medical or mental health conditions, such as bipolar disorder, psychosis, seizures or autoimmune disease
  • Sleep disorders other than insomnia, or a home sleep test AHI > 15; current sleeping pill use or drugs that change sleep or weight
  • Being in, or planning to join, another sleep or weight loss program
  • Suicidal thoughts or severe depression (CES-D score ≥ 20)
  • Breastfeeding, pregnant or planning pregnancy in the next 14 months; drug or alcohol use disorder; daily smoking or nicotine use

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Female
  • 18 years of age or older
  • Histologically-confirmed Ductal Carcinoma In Situ (DCIS) or stage I-III invasive carcinoma of the breast
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Current BMI ≥ 25 kg/m2 and weight ≤ 400 lbs
  • Willing to lose 10% of body weight
  • Diagnosed within 10 years with histologically-confirmed DCIS or stage I-III invasive carcinoma of the breast
  • Completed local therapy (i.e. surgery and radiation therapy) and any planned preoperative or adjuvant chemotherapy/immunotherapy(/HER2) human epidermal growth factor receptor 2 therapy/targeted therapy at least 3months prior to enrollment (concomitant endocrine therapy allowed)
  • Completed all planned/elective surgeries >4 weeks before enrollment
  • Meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for Insomnia disorder
  • Self-reported initial sleep onset time and/or wake after sleep onset (WASO) time > 30 minutes, > 3 nights/week
  • Reports sleep problems present for ≥ 3 months
  • Insomnia Severity Index Score ≥ 9

Who cannot take part

  • Current use of medications that cause sleep disturbances or weight gain/loss. (-) Current sedative hypnotic use
  • Serious/uncontrolled medical or psychiatric condition likely to hinder participation in BWL or CBT-l (bipolar disorder, psychotic disorder, seizure disorders, autoimmune disease, etc.)
  • Sleep disorder other than insomnia (mild sleep apnea or moderate to severe sleep apnea successfully treated via positive airway pressure (PAP) therapy is permitted
  • History of unstable psychiatric disorder
  • Positive urine toxicology for recreational drugs of abuse; alcohol or substance use disorder as determined by Alcohol Use Disorders Identification Test, Adapted for Use in the United States (USAUDIT294) and/or Structured Clinical Interview (SCID)
  • Currently enrolled or planning to enroll in a sleep treatment or weight loss program (agree not to enroll for the duration of the study) (-) Home sleep test Apnea/hypopnea Index (AHI) > 15
  • Participants also agree not to enroll in such a program for the duration of study participation (regardless of randomization)
  • Self-reported suicidal ideation or severe depressive symptoms as determined by clinical assessment, triggered by score of ≥ 20 on the Center for Epidemiologic Studies Depression (CES-D)
  • Lactating, pregnant or plan to become pregnant in next 14 months
  • Daily smoker/nicotine user
  • Anything that, in the opinion of the investigator, would place the subject at increased risk or preclude the patient's full compliance with or completion of the study

Where in United States

  • Johns Hopkins BayviewBaltimore, United StatesContact: Katie Smith, BATaking people
  • Sidney Kimmel Comprehensive Cancer Center, the Avon Foundation Breast Center at Johns HopkinsBaltimore, United StatesContact: Katie Smith, BATaking people
  • Johns Hopkins Kimmel Cancer Center at Greenspring StationLutherville, United StatesContact: Katie Smith, BATaking people
  • Sibley Memorial HospitalWashington D.C., United StatesContact: Katie Smith, BATaking people

About the trial

What the trial wants to find out

The investigators propose a randomized controlled clinical trial in 250 women with a history of early stage breast cancer who are overweight or obese with insomnia to test whether a brief, cognitive-behavioral intervention for insomnia (CBT-I) prior to behavioral weight loss (CBT-I+BWL) is superior to a sleep education control (EDU) condition followed by behavioral weight loss (EDU+BWL). The investigators will measure outcomes at baseline, 8 weeks (after completing CBT-I or EDU and prior to BWL), and at 3, 6, and 12 months.

The 2 groups in the trial

  • Cognitive-Behavioral Therapy for Insomnia (CBT-I)Treatment being tested

    The proposed intervention consists of 6 remotely-delivered sessions; Weeks 1, 2, 4, 6, 7, and 8, with weeks 3 and 5 being "rest weeks". Session 1 will be 60-90 mins, Session 2 will be \~60 mins, and remaining visits are \~45 mins. The investigators propose a methodological innovation for CBT-I, which involves conducting 15-minute sessions every other month during the BWL intervention. Prior to these maintenance sessions, participants in the CBT-I+BWL group will complete electronic sleep diaries for one week and interventionists will use this information in sessions to sustain and enhance long-term outcomes by using MI to reinforce application of CBT-I session content.

  • Sleep Education Control (EDU)Placebo, for comparison

    The EDU intervention will parallel the CBT-I intervention in number, format and length of all sessions, including maintenance sessions. It provides basic information about sleep and cancer, widely available to the public. EDU content does not include any individualized behavioral instructions, sleep diary monitoring during the intervention, or behavior change counseling. Content is presented didactically only.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
Plain-language title
Treating insomnia before a weight loss program in breast cancer survivorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
23 February 2026